| Long-term Efficacy of Vitrectomy for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients Treated with Intravitreal Injections. |
|
In Hwan Cho, Un Chul Park, Hyeong Gon Yu |
1Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea. hgonyu@snu.ac.kr
2Department of Ophthalmology, Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
3Retinal Degeneration Research Lab, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea. |
| 유리체내주사치료에 반응하지 않는 망막분지정맥폐쇄 황반부종환자에서 유리체절제술의 장기효과 분석 |
|
조인환1,2,3⋅박운철1,3⋅유형곤1,3 |
|
서울대학교 의과대학 안과학교실1, 순천향대학교 의과대학 천안병원 안과학교실2, 서울대학교병원 의생명연구원 망막변성연구소3 |
Correspondence:
Hyeong Gon Yu,
Email: hgonyu@snu.ac.kr
|
|
Received: 2 February 2017 • Revised: 29 March 2017 • Accepted: 25 April 2017 |
| Abstract |
PURPOSE
To evaluate the long-term efficacy of pars plana vitrectomy (PPV) on refractory or recurrent macular edema due to branch retinal vein occlusion (BRVO) after intravitreal steroid or anti-vascular endothelial growth factor injections. METHODS: We retrospectively reviewed the medical records of patients with macular edema due to BRVO who underwent PPV after intravitreal triamcinolone acetonide or bevacizumab injections and followed-up for at least 12 months. The best corrected visual acuity (BCVA) and subfoveal macular thickness were measured at 1, 3, 6, 12 months postoperatively and were compared with the preoperative values. The patients received additional intravitreal injections if they had recurrence of macular edema after surgery. The frequency of intravitreal injections (per year) were compared pre- and postoperatively. RESULTS: A total of 41 eyes of 41 patients were included and the mean duration of follow up was 58.7 ± 30.0 (15 - 124) months. The BCVA (logMAR) at 1, 3, 6, 12 months postoperatively, and last follow up was 0.52 ± 0.42, 0.46 ± 0.38, 0.41 ± 0.26, 0.50 ± 0.34, and 0.49 ± 0.37, respectively, which was significantly different from the preoperative values (0.90 ± 0.47, p < 0.001). The subfoveal macular thickness at 1, 3, 6, 12 months postoperatively, and last follow up was 342.72 ± 84.10 µm, 365.02 ± 110.73 µm, 359.45 ± 119.28 µm, 360.96 ± 124.33 µm, and 329.34 ± 119.69 µm, respectively, which was also significantly different (p < 0.001) from the preoperative values (484.9 ± 112.8 µm, p < 0.001). The frequency of intravitreal injections was significantly decreased after surgery (3.58 ± 2.05 times/year vs. 0.60 ± 0.83 times/year, p < 0.001). CONCLUSIONS: Pars plana vitrectomy could improve BCVA, decrease subfoveal macular thickness, and decrease recurrence in BRVO patients with refractory or recurrent macular edema after intravitreal injection. PPV could be an effective treatment option for these patients. |
| Key Words:
Branch retinal vein occlusion;Intravitreal injection;Pars plana vitrectomy |
|
PDF Links
Full text via DOI
Download Citation
